Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

4 years ago
Deals
R&D

SEC and FTC open two more in­ves­ti­ga­tions in­to Bio­gen's con­tro­ver­sial Alzheimer's drug ap­proval and mar­ket­ing ...

4 years ago
Pharma

With fin­ish line in sight, Brig­gs Mor­ri­son steps aside from Syn­dax CEO seat, swaps role with long­time col­league

4 years ago
People

Biotech bear mar­ket be damned, CAR-T play­er Ar­cel­lx rais­es $123M IPO

4 years ago
Financing
Cell/Gene Tx

Lyell CSO: New job is 'the miss­ing piece' of his ca­reer; Or­p­hazyme and Cor­texyme and Sio, oh my: Your guide to the ...

4 years ago
Peer Review

An­oth­er mi­cro­cap biotech plots ma­jor job cuts as in­dus­try sharp­ens its axe amid slow­down

4 years ago
People
R&D

'We need to do more': Mer­ck CEO Rob Davis high­lights M&A, deals strat­e­gy ahead of '28 Keytru­da patent cliff

4 years ago
R&D

Must-pass user fee deals: Bio­phar­ma com­pa­nies fund more than 80% of FDA's re­view staff, CDER head tells Con­gress

4 years ago
Pharma
FDA+

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug ...

4 years ago
R&D
Pharma

Roche re­gains pre-pan­dem­ic sales foot­ing, high­lights burst­ing pipeline — with one key fail­ure

4 years ago
Pharma

Take­da aban­dons one of its top ex­per­i­men­tal drugs fol­low­ing a slap down at the FDA

4 years ago
FDA+

A new Sen­ate bill is filled with calls for bet­ter pre­pared­ness for pan­demics go­ing for­ward

4 years ago
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Con­struc­tion un­der­way on Mo­roc­co's $562M vac­cine plant; Ar­genti­na be­gins Sput­nik ...

4 years ago
Manufacturing

I-Mab ex­pands man­u­fac­tur­ing for mul­ti­ple myelo­ma an­ti­body; Gran­ules is­sued 'mi­nor ob­ser­va­tion­s' af­ter in­spec­tion

4 years ago
Manufacturing

All for one: Sanofi un­veils mod­ern new cor­po­rate brand — and bids adieu to Pas­teur and Gen­zyme names

4 years ago
Pharma
Marketing

As­traZeneca dumps off a mid-stage PAD hope­ful, sound­ing re­treat from a packed mar­ket

4 years ago
Deals
R&D

Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

4 years ago
R&D
News Briefing

Bleed­ing cash from its Alzheimer's fran­chise, Bio­gen preps 'deals of all sizes' as rev­enue shriv­els

4 years ago
Pharma

Ra­jeev Venkayya, Take­da’s long­time vac­cines chief, de­parts to lead a stealth pan­dem­ic-fo­cused biotech

4 years ago
People

Opin­ion: A place­bo-con­trolled tri­al re­quire­ment from CMS will spell the end of Bio­gen's con­tro­ver­sial Alzheimer's ...

4 years ago
Pharma

Am­gen, look­ing for a path in­to red-hot 'mol­e­c­u­lar glues,' inks a deal with Plex­i­um for 2 pro­grams, po­ten­tial­ly more

4 years ago
Deals

Search­ing for CRISPR 2.0, In­tel­lia spends $45M cash on an un­known Berke­ley spin­out

4 years ago
Cell/Gene Tx

A rar­i­ty for ICER: Cost watch­dog says Covid-19 ther­a­peu­tics ap­pro­pri­ate­ly priced in the US

4 years ago
Pharma
Coronavirus

Cod­ed cal­en­dar in­vites, covert emails and delet­ed doc­u­ments: Pfiz­er sues ex-em­ploy­ees for al­leged­ly steal­ing trade ...

4 years ago
People
Pharma
First page Previous page 588589590591592593594 Next page Last page
A service from the Financial Times